Accueil   Diary - News   All news Presentation at American Neurological Association Congress Confirms Potential of GeNeuro’s Novel anti-HERV-K Antibody for Amyotrophic lateral sclerosis

Presentation at American Neurological Association Congress Confirms Potential of GeNeuro’s Novel anti-HERV-K Antibody for Amyotrophic lateral sclerosis


▪ Dr. Avindra Nath, Clinical Director of National Institute of Neurological Disorders and Stroke (NINDS), presented novel pre-clinical results of the Amyotrophic lateral
sclerosis (ALS) research program developed in partnership with GeNeuro


▪  Results: 


o confirm that HERV-K ENV is present in the cerebro-spinal fluid of sporadic ALS patients;
o elucidate the pathogenic effect of HERV-K ENV on motor neurons; and
o show in preclinical models the therapeutic potential of GeNeuro’s specific antiHERV-K ENV antibody. .

 


Geneva, Switzerland, 18 October, 2021 – 7:30am CEST – GeNeuro (Euronext Paris: CH0308403085 - GNRO), a biopharmaceutical company developing new treatments for neurological and autoimmune diseases, announced today that the NINDS, part of the U.S. National Institutes of Health (NIH), presented novel pre-clinical results at the American Neurological Association (ANA) annual meeting, October 17-19, confirming in pre-clinical models of ALS the neurotoxic properties of HERV-K ENV, a retroviral envelope protein encoded by a pathogenic member of the HERV-K family of endogenous human retroviruses, and the therapeutic potential of GeNeuro's antibody developed to neutralize HERV-K ENV.

 

 

Read the press release